ES2187814T3 - Derivados de pirazolopiridinopiridazinonas y procedimiento para su preparacion. - Google Patents

Derivados de pirazolopiridinopiridazinonas y procedimiento para su preparacion.

Info

Publication number
ES2187814T3
ES2187814T3 ES97941255T ES97941255T ES2187814T3 ES 2187814 T3 ES2187814 T3 ES 2187814T3 ES 97941255 T ES97941255 T ES 97941255T ES 97941255 T ES97941255 T ES 97941255T ES 2187814 T3 ES2187814 T3 ES 2187814T3
Authority
ES
Spain
Prior art keywords
sup
sub
procedure
derivatives
lower alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97941255T
Other languages
English (en)
Inventor
Yasushi Kouno
Takenobu Ogata
Katsuya Awano
Kayoko Matsuzawa
Taroh Tooru
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyorin Pharmaceutical Co Ltd
Original Assignee
Kyorin Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyorin Pharmaceutical Co Ltd filed Critical Kyorin Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2187814T3 publication Critical patent/ES2187814T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Nuevos derivados de pirazolpiridilpiridazinona caracterizados porque están representados por la fórmula general (1) y sus sales farmacológicamente aceptables, que presentan una actividad inhibidora de fosfodiesterasa y tienen un potente efecto selectivo de broncodilatación sobre las vías respiratorias: un procedimiento para preparar estos compuestos y broncodilatadores que los contienen como ingrediente activo: en la que R{sup,1} es un alquilo inferior C{sub,1-4} o cicloalquilo C{sub,3-6} y R{sup,2}, R{sup,3}, R{sup,4} y R{sup,5} son, independientemente, hidrógeno, alquilo o fenilo inferior C{sub,1-4}, o alternativamente R{sup,3} y R{sup,5} pueden estar unidos para formar un doble enlace.
ES97941255T 1996-10-04 1997-09-26 Derivados de pirazolopiridinopiridazinonas y procedimiento para su preparacion. Expired - Lifetime ES2187814T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP28314896 1996-10-04

Publications (1)

Publication Number Publication Date
ES2187814T3 true ES2187814T3 (es) 2003-06-16

Family

ID=17661845

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97941255T Expired - Lifetime ES2187814T3 (es) 1996-10-04 1997-09-26 Derivados de pirazolopiridinopiridazinonas y procedimiento para su preparacion.

Country Status (11)

Country Link
US (1) US6265577B1 (es)
EP (1) EP0989129B1 (es)
KR (1) KR100517397B1 (es)
CN (1) CN1083841C (es)
AT (1) ATE229527T1 (es)
AU (1) AU733316B2 (es)
CA (1) CA2267103C (es)
DE (1) DE69717867T2 (es)
ES (1) ES2187814T3 (es)
HU (1) HUP9903018A2 (es)
WO (1) WO1998014448A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410584B1 (en) 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
US6200771B1 (en) 1998-10-15 2001-03-13 Cell Pathways, Inc. Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
US6133271A (en) * 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6187779B1 (en) 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6369092B1 (en) 1998-11-23 2002-04-09 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6077842A (en) * 1998-11-24 2000-06-20 Cell Pathways, Inc. Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
US6034099A (en) * 1998-11-24 2000-03-07 Cell Pathways, Inc. Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
US6875575B1 (en) 1998-11-25 2005-04-05 Osi Pharmaceuticals, Inc. Diagnostic methods for neoplasia
US6020379A (en) * 1999-02-19 2000-02-01 Cell Pathways, Inc. Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
CA2715683A1 (en) 1999-08-21 2001-03-01 Nycomed Gmbh Synergistic combination
US7208516B2 (en) 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US7276529B2 (en) 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
EP1570847B1 (en) * 2002-12-03 2012-04-25 Kyorin Pharmaceutical Co., Ltd. Phosphodiesterase 10a inhibitors for use in the treatment of parkinson's disease, huntington's disease and schizophrenia
WO2006095666A1 (ja) * 2005-03-07 2006-09-14 Kyorin Pharmaceutical Co., Ltd. ピラゾロピリジン－４－イルピリダジノン誘導体とその付加塩及びそれらを有効成分とするｐｄｅ阻害剤
JP5352452B2 (ja) * 2006-06-06 2013-11-27 メディシノバ， インコーポレイテッド 置換ピラゾロ［１，５−ａ］ピリジン化合物およびその使用方法
US20100056791A1 (en) * 2006-09-01 2010-03-04 Yasushi Kohno Pyrazolopyridine carboxamide derivative and phosphodiesterase (pde) inhibitor containing the same
CA2661992A1 (en) * 2006-09-06 2008-03-13 Kyorin Pharmaceutical Co., Ltd. Pyrazolopyridine derivative and phosphodiesterase (pde) inhibitor containing the same as active ingredient
JP2010013354A (ja) * 2006-09-07 2010-01-21 Kyorin Pharmaceut Co Ltd ２−アルキル−６−（ピラゾロピリジン−４−イル）ピリダジノン誘導体とその付加塩及びそれらを有効成分とするｐｄｅ阻害剤
WO2008129624A1 (ja) * 2007-04-10 2008-10-30 Kyorin Pharmaceutical Co., Ltd. ピラゾロピリジン－４－イルピラゾロン誘導体とその付加塩及びそれを有効成分とするホスホジエステラーゼ阻害剤
WO2010035745A1 (ja) 2008-09-25 2010-04-01 杏林製薬株式会社 ヘテロ環ビアリール誘導体及びそれらを有効成分とするｐｄｅ阻害剤
EP2351748A4 (en) 2008-10-09 2012-03-21 Kyorin Seiyaku Kk ISOCHINOLINE DERIVATIVES AND THESE PDE INHIBITORS CONTAINING ACTIVE SUBSTANCE
BR122017025423B1 (pt) 2011-04-08 2021-05-11 Janssen Sciences Ireland Uc derivados de pirimidina, seu uso no tratamento de infecções virais e composição farmacêutica que os compreende
BR122019020718B1 (pt) 2011-11-09 2021-07-06 Janssen Sciences Ireland Uc Derivados purínicos para o tratamento de infecções virais e composição farmacêutica que os compreende
NZ702364A (en) 2012-07-13 2016-09-30 Janssen Sciences Ireland Uc Macrocyclic purines for the treatment of viral infections
JP6293765B2 (ja) 2012-10-10 2018-03-14 ヤンセン・サイエンシズ・アイルランド・ユーシー ウイルス感染症および他の疾患の処置のためのピロロ［３，２−ｄ］ピリミジン誘導体
BR112015011036B1 (pt) 2012-11-16 2022-02-01 Janssen Sciences Ireland Uc Derivados de 2-amino-quinazolina substituídos heterocíclicos, composição farmacêutica
EA035174B1 (ru) 2013-02-21 2020-05-12 Янссен Сайенсиз Айрлэнд Юси Производные 2-аминопиримидина в качестве модуляторов толл-подобных рецепторов tlr7 и/или tlr8
SG11201508078XA (en) 2013-03-29 2015-11-27 Janssen Sciences Ireland Uc Macrocyclic deaza-purinones for the treatment of viral infections
KR102280559B1 (ko) 2013-05-24 2021-07-22 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 바이러스 감염 및 추가적인 질환의 치료를 위한 피리돈 유도체
ES2645950T3 (es) 2013-06-27 2017-12-11 Janssen Sciences Ireland Uc Derivados de pirrolo[3,2-d]pirimidina para el tratamiento de infecciones víricas y otras enfermedades
JP6401788B2 (ja) 2013-07-30 2018-10-10 ヤンセン・サイエンシズ・アイルランド・ユーシー ウイルス感染治療用チエノ［３，２−ｄ］ピリミジン誘導体
US10300042B2 (en) 2014-06-23 2019-05-28 Celgene Corporation Apremilast for the treatment of a liver disease or a liver function abnormality
JP7171444B2 (ja) 2016-07-01 2022-11-15 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー ウイルス感染治療用のジヒドロピラノピリミジン
KR102450287B1 (ko) 2016-09-29 2022-09-30 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 바이러스 감염 및 추가적인 질환의 치료를 위한 피리미딘 프로드러그
TW201945003A (zh) 2018-03-01 2019-12-01 愛爾蘭商健生科學愛爾蘭無限公司 ２，４－二胺基喹唑啉衍生物及其醫學用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8901423D0 (en) * 1989-01-23 1989-03-15 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
GB9015764D0 (en) * 1990-07-18 1990-09-05 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
CA2060138A1 (en) * 1991-01-29 1992-07-30 Youichi Shiokawa New use of the adenosine antagonist

Also Published As

Publication number Publication date
AU4321397A (en) 1998-04-24
CA2267103A1 (en) 1998-04-09
EP0989129B1 (en) 2002-12-11
DE69717867T2 (de) 2003-10-02
HUP9903018A2 (hu) 2000-03-28
EP0989129A1 (en) 2000-03-29
DE69717867D1 (de) 2003-01-23
KR20000048874A (ko) 2000-07-25
CA2267103C (en) 2006-05-30
US6265577B1 (en) 2001-07-24
CN1083841C (zh) 2002-05-01
WO1998014448A1 (fr) 1998-04-09
ATE229527T1 (de) 2002-12-15
EP0989129A4 (en) 2001-04-11
AU733316B2 (en) 2001-05-10
CN1232463A (zh) 1999-10-20
KR100517397B1 (ko) 2005-09-29

Similar Documents

Publication Publication Date Title
ES2187814T3 (es) Derivados de pirazolopiridinopiridazinonas y procedimiento para su preparacion.
LTC1265862I2 (lt) 2-Okso-1-pirolidino dariniai, jų gamybos būdas ir jų panaudojimas
ES2175161T3 (es) Derivados de piperazina como antagonistas de taquiquinina.
ES2112650T3 (es) Sales de un derivado de indol antimigraña.
ES2158778B1 (es) Compuestos de sales de paroxetina, su preparacion y uso, y composiciones farmaceuticas que los contienen.
UY27092A1 (es) Derivados del novedoso carbamato de quinuclidina y las composiciones medicinales que los contienen
ES2094721T3 (es) Analogos de la camptotecina solubles en agua.
ES2164920T3 (es) Nuevos derivados heterociclicos y uso medicinal de los mismos.
BRPI0313942B8 (pt) derivados de benzimidazol úteis como agentes antiproliferativos, seus processos de preparação, composição farmacêutica compreendendo os mesmos e usos dos referidos compostos nas preparações de composições farmacêuticas
AR001332A1 (es) Nuevos compuestos antagonistas de la taquicinina, proceso para obtenerlos y composiciones farmaceuticas que los contienen.
AR023971A1 (es) Derivados de 4,5,6,7-tetrahidroindazol, procedimiento para la preparacion de los mismos y su utilizacion como agentes antitumorales
ES2160648T3 (es) Derivados de piridina.
DE69519469T2 (de) Chinazolin-derivate
LV12634A (lv) Watersoluble azole antifungals
DK253685A (da) Bis-triazol-cyclopropyl-ethanol-derivater, fremgangsmaade til fremstilling deraf samt anvendelse deraf som fungicid eller laegemiddel
NO20045132L (no) Benzo(c)kinolizinderivater, deres fremstilling og anvendelse som 5alfa- reduktaseinhibitorer
ES2172436B1 (es) Derivados de indolilpiperidina como agentes antihistaminicos y antialergicos.
MX9306178A (es) Bencimidazoles medicamentos que contienen estos compuestos yprocedimientos para su preparacion.
ES2157498T3 (es) Derivados de triazol o sus sales.
AR019975A1 (es) Derivados de feniletilamina, procedimiento para su preparacion, preparado farmaceutico que los contiene y su utilizacion
ES2159098T3 (es) Nuevos derivados de elipticina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
AR026682A1 (es) Compuesto de carbapenem, uso del mismo y de su compuesto intermediario
ATE297939T1 (de) Herstellung von kristallinen polymorphen von fosinopril natrium
ES2157542T3 (es) Nuevos derivados de elipticina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ECSP024374A (es) Derivados del 4,5-dihidro-tiazol-2-ylamina y sus usos como inhibidores de no sintetasa